Clinical Trial Update: Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST [Phase 1, Phase 2]

View source ↗

Summary

An early-phase clinical trial is evaluating the combination of a MEK inhibitor and an MDM2 inhibitor in patients with Neurofibromatosis type 1 and Malignant Per…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Neurofibroma
• Malignant Peripheral Nerve Sheath Tumor
• Neurofibromatosis Type

Drugs mentioned

• MDM2 inhibitor
• MEK inhibitor

Snippet

Sponsor: AeRang Kim | Conditions: Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING